drugset
drugset / Trial / NCT01561781

Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib

NCT01561781 ↗

Phase 1 Completed 14 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelBasic science

Summary

This is a study in healthy volunteers to assess the pharmacokinetics (PK) of Digoxin administered alone and in combination with Vandetanib.

Timeline

Start
2012-03
Primary completion
2012-07
Completion
2012-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Vandetanib Small molecule 300 mg Oral

Indications

No indication recorded.